EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Systemic administration of Resolvin D1 reduces cancer‐induced bone pain in mice: Lack of sex dependency in pain development and analgesia

Alyssa Flippen, Iryna A Khasabova, Donald A Simone, Sergey G Khasabov iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.70077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Alyssa Flippen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Biological Sciences, School of Dentistry, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Bone Neoplasms, Cancer Pain, Docosahexaenoic Acids, Hyperalgesia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Bone cancer produces severe pain that is treated with opioids, but serious side effects limit opioid utilization. There is therefore a need to develop effective and safe non‐opioid alternatives. The lipid mediator, Resolvin D1 (RvD1), could be a prospective candidate for cancer pain treatment. To assess RvD1 and other potential candidates, appropriate animal models that recapitulate clinical features must be used. Although several preclinical models of cancer pain have been developed, the influence of sex on the development of cancer pain and the effectiveness of RvD1 have not been studied.

Results

Using a mouse model of fibrosarcoma growth in and around the calcaneus bone, we demonstrated that the mechanical hyperalgesia in the tumor‐bearing hind paw develops independently of sex, except that it developed a little sooner in female mice. A single intravenous injection of RvD1 (0.001–10 μg/kg) decreased hyperalgesia in both sexes with similar potency (ED 50 = 0.0015 μg/kg) and efficacy. Repeated daily administration of 10 μg/kg RvD1 prolonged the analgesic effect and completely abolished hyperalgesia. This was also independent of sex.

Conclusion

In this preclinical mouse model of bone cancer pain, the development of pain and the analgesic effectiveness of RvD1 are not influenced by sex.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsCancer PainDocosahexaenoic AcidsHyperalgesiaDisease Models, AnimalAnimalsFemaleMaleMiceAnalgesicsFibrosarcomaSex FactorsPain Measurement

Stichwörter der Autor:innen

Resolvin D1antinociceptionbone cancer painmicesex difference

Substanzen

resolvin D1Docosahexaenoic AcidsAnalgesics

Autor:innen und Institutionen

  • Department of Diagnostic and Biological Sciences, School of Dentistry, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: Sergey G Khasabov

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Flippen, A., Khasabova, I. A., Simone, D. A., & Khasabov, S. G. (2024). Systemic administration of Resolvin D1 reduces cancer‐induced bone pain in mice: Lack of sex dependency in pain development and analgesia. Cancer Medicine. https://doi.org/10.1002/cam4.70077

Vancouver

Flippen A, Khasabova IA, Simone DA, Khasabov SG. Systemic administration of Resolvin D1 reduces cancer‐induced bone pain in mice: Lack of sex dependency in pain development and analgesia. Cancer Medicine. 2024. doi:10.1002/cam4.70077

BibTeX
@article{Flippen2024,
  author = {Flippen, Alyssa and Khasabova, Iryna A and Simone, Donald A and Khasabov, Sergey G},
  title = {Systemic administration of Resolvin D1 reduces cancer‐induced bone pain in mice: Lack of sex dependency in pain development and analgesia},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70077}
}
Kostenlos starten →